Ocu­gen hits an­oth­er snag in bring­ing its Bharat Biotech-part­nered Covid-19 vac­cine to the US

Back in Ju­ly, Ocu­gen and Bharat Biotech un­veiled some Phase III da­ta sug­gest­ing their Covid-19 vac­cine, Co­v­ax­in, was 77.8% ef­fec­tive at pre­vent­ing over­all dis­ease in In­dia. They’re now look­ing to launch an im­muno-bridg­ing study to see if those num­bers hold up in the US — but on Fri­day, the FDA said not so fast.

Reg­u­la­tors have placed a clin­i­cal hold on the part­ners’ IND, Ocu­gen shared on Fri­day. Ocu­gen’s stock $OCGN sank 9% on the news Fri­day, but was up al­most 7% in pre-mar­ket trad­ing on Mon­day.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN